Can-Fite Biopharma Ltd
CANF
Positions held
Your positionsCANF isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $6.06M | Enterprise value | -$2.71M | Trailing P/E | — | Forward P/E | -2.20 |
| PEG | — | Price / book | 0.88 | Beta | -0.02 | Dividend yield | 0.00% |
| Revenue growth | 0.0% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -23.2% |
| Profit margin | 0.0% | ROE | -2.1% | ROA | -77.1% | Debt / equity | 0.01 |
| Current ratio | 3.60 | Free cash flow | -$5.58M | Analyst recommendation | strong_buy | Mean target | $8.00 |
| 52w high | $12.40 | 52w low | $1.96 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.4M | $0.7M | $0.7M | $0.8M | — |
| Op margin | -2456.8% | -1206.2% | -1103.0% | -1246.4% | — |
| Net income | -$9.8M | -$7.9M | -$7.6M | -$10.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$9.9M | -$8.1M | -$8.2M | -$10.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-02 · Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
2026-09-02 · Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
2026-08-17 · Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
2026-08-12 · Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
2026-08-03 · Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Price (daily)
Full chart · RSI · MACD · patterns